Admixture-informed polygenic risk reporting using the ePRS framework
Yu-Jyun Huang1,2, Nuzulul Kurniansyah3, Matthew O Goodman1,3
1Department of Medicine, Harvard Medical School, Boston, MA, USA.
Nature Communications
|April 30, 2026
Summary
Polygenic risk scores (PRS) can be calibrated using ancestral makeup. The proposed expected PRS (ePRS) and residual PRS (rPRS) framework offers an equitable strategy for interpreting genetic risk across diverse populations.
Area of Science:
- Genetics
- Population Genetics
- Statistical Genetics
Background:
- Polygenic risk scores (PRS) exhibit variability across different genetic ancestries due to population-specific allele frequencies and linkage disequilibrium.
- Existing PRS methods often struggle with population stratification, leading to biased association estimates.
Purpose of the Study:
- To introduce a novel framework for calibrating polygenic risk scores based on an individual's ancestral makeup.
- To define and validate the expected polygenic risk score (ePRS) and residual polygenic risk score (rPRS) for improved PRS interpretation.
Main Methods:
- Developed the expected polygenic risk score (ePRS) as the expected PRS value based on global or local admixture patterns.
- Defined the residual polygenic risk score (rPRS) as the deviation of PRS from ePRS, representing an ancestry-agnostic genetic liability.
- Validated the framework using simulation studies and real-world datasets (TOPMed and All of Us).
Main Results:
- Simulation studies demonstrated that adjusting for ePRS yields unbiased polygenic risk score-outcome association estimates without needing principal components.
- Effect size estimates for rPRS (adjusted for ePRS) were comparable to traditional PRS methods that adjust for genetic principal components.
- The ePRS framework effectively mitigates population stratification in association analyses.
Conclusions:
- The ePRS framework provides a robust method for calibrating polygenic risk scores across diverse populations.
- This approach enhances the equitable interpretation of genetic risk by separating ancestry-driven components from ancestry-agnostic liability.
- The ePRS framework offers a promising strategy for accurate and equitable genetic risk assessment in population genetics and precision medicine.
More Related Videos
Related Concept Videos
Polygenic Traits
58.4K
When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
58.4K
Polygenic Traits
7.1K
7.1K
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138


